CIAM
IMDX

Caitong International Asset Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Caitong International Asset Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$266 Buy
45
+44
+4,400% +$217 ﹤0.01% 1930
2026
Q1 		$3 Buy
+1
New +$6 ﹤0.01% 2389

Other funds holding IMDX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
FOR
Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Caitong International Asset Management's IMDX Position: Q2 2026 in Review

Caitong International Asset Management increased its Insight Molecular Diagnostics (IMDX) stake by 4,400% in Q2 2026, buying an estimated $217 and bringing the position to 45 shares worth $266. The position accounts for ﹤0.01% of the portfolio, ranked #1930.

Caitong International Asset Management first reported a position in IMDX in Q1 2026 and has held it in 2 quarters since. 40 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • Caitong International Asset Management held 45 shares of Insight Molecular Diagnostics worth $266 as of Q2 2026.
  • Caitong International Asset Management bought 44 Insight Molecular Diagnostics shares in Q2 2026, an estimated $217.
  • Insight Molecular Diagnostics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1930 holding.
  • Caitong International Asset Management first reported a position in Insight Molecular Diagnostics in Q1 2026 and has held it in 2 quarters since.
  • 40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.